Vitiligo
☆ V rezultatih raziskave Stiftung Warentest iz Nemčije leta 2022 je bilo zadovoljstvo potrošnikov z ModelDermom le nekoliko nižje kot s plačanimi telemedicinskimi svetovanji.
Vitiligo na prstih je težje zdraviti kot na drugih področjih. Poleg tega, da je vitiligo kozmetično neprijeten, je normalen in ni nalezljiv. V dermatologiji je najučinkovitejše zdravljenje fototerapija ali lasersko zdravljenje (excimer) 2-3x tedensko vsaj 1 leto. Če zaradi finančnih razlogov ali zaradi zasedenosti ne morete pogosto hoditi v bolnišnico, lahko poskusite z napravo za fototerapijo, ki je odobrena za domačo uporabo.
Vitiligo vek
Vitiligo na roki
References
Vitiligo je pogosta kožna bolezen, ki povzroča lise bele kože zaradi izgube melanocitov. Novejše raziskave kažejo, da gre za avtoimunsko bolezen. Čeprav se na to pogosto gleda kot na kozmetično težavo, lahko močno vpliva na duševno počutje in vsakdanje življenje. Leta 2011 so strokovnjaki tip, imenovan segmental vitiligo , razvrstili ločeno od drugih.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Bolniki z aktivnim vitiligom imajo več možnosti zdravljenja, kot so sistemski glukokortikoidi, fototerapija in sistemski imunosupresivi. Stabilni bolniki z vitiligom lahko najdejo olajšanje z lokalnimi kortikosteroidi, lokalnimi zaviralci kalcinevrina, fototerapijo in postopki presaditve. Nedavni napredek pri razumevanju osnovnih procesov vitiliga je privedel do razvoja ciljnih terapij. Trenutno so najbolj obetavni zaviralci JAK, ki nudijo dobro prenašanje in funkcionalne rezultate, kljub tveganju za aktiviranje latentnih okužb in sistemskih neželenih učinkov, ki so pogosti pri drugih imunosupresivih. Namen tekočih raziskav je identificirati ključne citokine, ki sodelujejo pri razvoju vitiliga (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . Blokiranje teh citokinov je bilo obetavno na živalskih modelih in nekaterih bolnikih. Poleg tega potekajo preiskave miRNA-based therapeutics in adoptive Treg cell therapy.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Za vitiligo ni znanega zdravila. Za tiste s svetlo poltjo se običajno priporočata samo krema za sončenje in ličila. Druge možnosti zdravljenja lahko vključujejo steroidne kreme ali fototerapijo.
○ zdravljenje
#Phototherapy
#Excimer laser
#Tacrolimus ointment